GAD-alum treatment induces GAD 65 -specific CD4 + CD25 high FOXP3 + cells in type 1 diabetic patients

Clinical Immunology

Volumn 138, Issue 1, 2011, Pages 117-126

  Hjorth, Maria ^a   Axelsson, Stina ^a   Rydén, Anna ^a   Faresjö, Maria ^a   Ludvigsson, Johnny ^a   Casas, Rosaura ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Antigen specific cell; Cytokine; FOXP3; Immunotherapy; Type 1 diabetes

Indexed keywords

ALUMINUM; DIAMYD; GAMMA INTERFERON; GLUTAMATE DECARBOXYLASE 65; GLUTAMATE DECARBOXYLASE ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 5; INTERLEUKIN 6; MESSENGER RNA; PLACEBO; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CHILD; CYTOKINE RELEASE; DRUG FORMULATION; DRUG MECHANISM; FEMALE; HUMAN; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD; TH2 CELL;

EID: 78651374710     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2010.10.004     Document Type: Article

References (49)

1. Atkinson M.A., Bowman M.A., Campbell L., Darrow B.L., Kaufman D.L., Maclaren N.K. Cellular immunity to a determinant common to glutamate decarboxylase and Coxsackie virus in insulin-dependent diabetes. J. Clin. Invest. 1994, 94:2125-2129.
2. Coutant R., Landais P., Rosilio M., Johnsen C., Lahlou N., Chatelain P., Carel J.C., Ludvigsson J., Boitard C., Bougneres P.F. Low dose linomide in Type I juvenile diabetes of recent onset: a randomised placebo-controlled double blind trial. Diabetologia 1998, 41:1040-1046.
3. Bougneres P.F., Carel J.C., Castano L., Boitard C., Gardin J.P., Landais P., Hors J., Mihatsch M.J., Paillard M., Chaussain J.L., et al. Factors associated with early remission of type I diabetes in children treated with cyclosporine. N Engl J. Med. 1988, 318:663-670.
4. Herold K.C., Gitelman S.E., Masharani U., Hagopian W., Bisikirska B., Donaldson D., Rother K., Diamond B., Harlan D.M., Bluestone J.A. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2years after onset of type 1 diabetes. Diabetes 2005, 54:1763-1769.
5. Pescovitz M.D., Greenbaum C.J., Krause-Steinrauf H., Becker D.J., Gitelman S.E., Goland R., Gottlieb P.A., Marks J.B., McGee P.F., Moran A.M., Raskin P., Rodriguez H., Schatz D.A., Wherrett D., Wilson D.M., Lachin J.M., Skyler J.S. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J. Med. 2009, 361:2143-2152.
6. Tisch R., McDevitt H.O. Antigen-specific immunotherapy: is it a real possibility to combat T-cell-mediated autoimmunity?. Proc. Natl Acad. Sci. USA 1994, 91:437-438.
7. Wang B., Tisch R. Parameters influencing antigen-specific immunotherapy for Type 1 diabetes. Immunol. Res. 2008, 42:246-258.
8. Skyler J.S., Krischer J.P., Wolfsdorf J., Cowie C., Palmer J.P., Greenbaum C., Cuthbertson D., Rafkin-Mervis L.E., Chase H.P., Leschek E. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial-Type 1. Diab. Care 2005, 28:1068-1076.
9. Orban T., Farkas K., Jalahej H., Kis J., Treszl A., Falk B., Reijonen H., Wolfsdorf J., Ricker A., Matthews J.B., Tchao N., Sayre P., Bianchine P. Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy. J. Autoimmun. 2009, 408-415.
10. Schloot N.C., Meierhoff G., Lengyel C., Vandorfi G., Takacs J., Panczel P., Barkai L., Madacsy L., Oroszlan T., Kovacs P., Suto G., Battelino T., Hosszufalusi N., Jermendy G. Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials. Diab. Metab. Res. Rev. 2007, 23:276-285.
11. Eldor R., Kassem S., Raz I. Immune modulation in type 1 diabetes mellitus using DiaPep277: a short review and update of recent clinical trial results. Diab. Metab. Res. Rev. 2009, 25:316-320.
12. Pozzilli P., Leslie R.D. New prospects for immunotherapy at diagnosis of type 1 diabetes. Diab. Metab. Res. Rev. 2009, 25:299-301.
13. Kaufman D.L., Clare-Salzler M., Tian J., Forsthuber T., Ting G.S., Robinson P., Atkinson M.A., Sercarz E.E., Tobin A.J., Lehmann P.V. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 1993, 366:69-72.
14. Baekkeskov S., Kanaani J., Jaume J.C., Kash S. Does GAD have a unique role in triggering IDDM?. J. Autoimmun. 2000, 15:279-286.
15. Tisch R., Liblau R.S., Yang X.D., Liblau P., McDevitt H.O. Induction of GAD65-specific regulatory T-cells inhibits ongoing autoimmune diabetes in nonobese diabetic mice. Diabetes 1998, 47:894-899.
16. Jun H.S., Chung Y.H., Han J., Kim A., Yoo S.S., Sherwin R.S., Yoon J.W. Prevention of autoimmune diabetes by immunogene therapy using recombinant vaccinia virus expressing glutamic acid decarboxylase. Diabetologia 2002, 45:668-676.
17. Tian J., Atkinson M.A., Clare-Salzler M., Herschenfeld A., Forsthuber T., Lehmann P.V., Kaufman D.L. Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J. Exp. Med. 1996, 183:1561-1567.
18. Tisch R., Wang B., Atkinson M.A., Serreze D.V., Friedline R. A glutamic acid decarboxylase 65-specific Th2 cell clone immunoregulates autoimmune diabetes in nonobese diabetic mice. J. Immunol. 2001, 166:6925-6936.
19. Agardh C.D., Cilio C.M., Lethagen A., Lynch K., Leslie R.D., Palmer M., Harris R.A., Robertson J.A., Lernmark A. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J. Diab. Complications 2005, 19:238-246.
20. Ludvigsson J., Faresjo M., Hjorth M., Axelsson S., Cheramy M., Pihl M., Vaarala O., Forsander G., Ivarsson S., Johansson C., Lindh A., Nilsson N.O., Aman J., Ortqvist E., Zerhouni P., Casas R. GAD Treatment and Insulin Secretion in Recent-Onset Type 1 Diabetes. N Engl J. Med. 2008, 1909-1920.
21. Dejaco C., Duftner C., Grubeck-Loebenstein B., Schirmer M. Imbalance of regulatory T cells in human autoimmune diseases. Immunology 2006, 117:289-300.
22. Schneider A., Rieck M., Sanda S., Pihoker C., Greenbaum C., Buckner J.H. The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells. J. Immunol. 2008, 181:7350-7355.
23. Masteller E.L., Tang Q., Bluestone J.A. Antigen-specific regulatory T cells-ex vivo expansion and therapeutic potential. Semin. Immunol. 2006, 18:103-110.
24. Tang Q., Henriksen K.J., Bi M., Finger E.B., Szot G., Ye J., Masteller E.L., McDevitt H., Bonyhadi M., Bluestone J.A. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J. Exp. Med. 2004, 199:1455-1465.
25. Liu C.P. Glutamic acid decarboxylase-specific CD4+ regulatory T cells. Ann. NY Acad. Sci. 2006, 1079:161-170.
26. Huter E.N., Stummvoll G.H., DiPaolo R.J., Glass D.D., Shevach E.M. Cutting edge: antigen-specific TGF beta-induced regulatory T cells suppress Th17-mediated autoimmune disease. J. Immunol. 2008, 181:8209-8213.
27. Bresson D., von Herrath M. Resuscitating adaptive Tregs with combination therapies?. Novartis Found. Symp. 2008, 292:50-60. (discussion 60-7, 122-9, 202-3).
28. Long S.A., Walker M.R., Rieck M., James E., Kwok W.W., Sanda S., Pihoker C., Greenbaum C., Nepom G.T., Buckner J.H. Functional islet-specific Treg can be generated from CD4+CD25- T cells of healthy and type 1 diabetic subjects. Eur. J. Immunol. 2009, 39:612-620.
29. Bresson D., Togher L., Rodrigo E., Chen Y., Bluestone J.A., Herold K.C., von Herrath M. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J. Clin. Invest. 2006, 116:1371-1381.
30. Jonson C.O., Hedman M., Karlsson Faresjo M., Casas R., Ilonen J., Ludvigsson J., Vaarala O. The association of CTLA-4 and HLA class II autoimmune risk genotype with regulatory T cell marker expression in 5-year-old children. Clin. Exp. Immunol. 2006, 145:48-55.
31. Walker M.R., Kasprowicz D.J., Gersuk V.H., Benard A., Van Landeghen M., Buckner J.H., Ziegler S.F. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells. J. Clin. Invest. 2003, 112:1437-1443.
32. Wang J., Ioan-Facsinay A., van der Voort E.I., Huizinga T.W., Toes R.E. Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur. J. Immunol. 2007, 37:129-138.
33. Allan S.E., Crome S.Q., Crellin N.K., Passerini L., Steiner T.S., Bacchetta R., Roncarolo M.G., Levings M.K. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int. Immunol. 2007, 19:345-354.
34. Mjosberg J., Svensson J., Johansson E., Hellstrom L., Casas R., Jenmalm M.C., Boij R., Matthiesen L., Jonsson J.I., Berg G., Ernerudh J. Systemic reduction of functionally suppressive CD4dimCD25highFoxp3+ Tregs in human second trimester pregnancy is induced by progesterone and 17beta-estradiol. J. Immunol. 2009, 183:759-769.
35. Hoffmann P., Eder R., Kunz-Schughart L.A., Andreesen R., Edinger M. Large-scale in vitro expansion of polyclonal human CD4(+)CD25high regulatory T cells. Blood 2004, 104:895-903.
36. Axelsson S., Faresjo M., Hedman M., Ludvigsson J., Casas R. Cryopreserved peripheral blood mononuclear cells are suitable for the assessment of immunological markers in type 1 diabetic children. Cryobiology 2008, 201-208.
37. Cheandacute;ramy M., et al. GAD-alum treatment in patients with type 1 diabetes and the subsequent effect on GADA IgG subclass distribution, GAD65 enzyme activity and humoral response. Clin. Immunol. 2010, 137:31-40.
38. Chen L.C., Delgado J.C., Jensen P.E., Chen X. Direct expansion of human allospecific FoxP3+CD4+ regulatory T cells with allogeneic B cells for therapeutic application. J. Immunol. 2009, 183:4094-4102.
39. Wan Y.Y., Flavell R.A. Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression. Nature 2007, 445:766-770.
40. Belghith M., Bluestone J.A., Barriot S., Megret J., Bach J.F., Chatenoud L. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat. Med. 2003, 9:1202-1208.
41. Bisikirska B., Colgan J., Luban J., Bluestone J.A., Herold K.C. TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J. Clin. Invest. 2005, 115:2904-2913.
42. DiPaolo R.J., Glass D.D., Bijwaard K.E., Shevach E.M. CD4+CD25+ T cells prevent the development of organ-specific autoimmune disease by inhibiting the differentiation of autoreactive effector T cells. J. Immunol. 2005, 175:7135-7142.
43. Chatenoud L. CD3-specific antibody-induced active tolerance: from bench to bedside. Nat. Rev. Immunol. 2003, 3:123-132.
44. Axelsson S., Hjorth M., Akerman L., Ludvigsson J., Casas R. Early induction of GAD(65)-reactive Th2 response in type 1 diabetic children treated with alum-formulated GAD(65). Diab. Metab. Res. Rev. 2010, 26:559-568.
45. Seder R.A., Darrah P.A., Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat. Rev. Immunol. 2008, 8:247-258.
46. Darrah P.A., Patel D.T., De Luca P.M., Lindsay R.W., Davey D.F., Flynn B.J., Hoff S.T., Andersen P., Reed S.G., Morris S.L., Roederer M., Seder R.A. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat. Med. 2007, 13:843-850.
47. Lindenstrom T., Agger E.M., Korsholm K.S., Darrah P.A., Aagaard C., Seder R.A., Rosenkrands I., Andersen P. Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J. Immunol. 2009, 182:8047-8055.
48. Gray D., Gray M., Barr T. Innate responses of B cells. Eur. J. Immunol. 2007, 37:3304-3310.
49. Mann M.K., Maresz K., Shriver L.P., Tan Y., Dittel B.N. B cell regulation of CD4+CD25+ T regulatory cells and IL-10 via B7 is essential for recovery from experimental autoimmune encephalomyelitis. J. Immunol. 2007, 178:3447-3456.